SCHEMBL3170923

SCHEMBL3170923

CCCc1ccc2c(F)c(-c3ccc(-c4ccc(OC(F)(F)F)cc4)cc3)ccc2c1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.37
GRM2 Q14416 2/20 0.36
CHRNA7 P36544 1/20 0.36
TSHR P16473 1/20 0.35
CHRM5 P08912 2/20 0.35
PPARA Q07869 1/20 0.35
NCEH1 Q6PIU2 2/20 0.34
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
SERPINE1 P05121 1/20 0.34
MPL P40238 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
PTGER4 P35408 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3162399 0.99 GRM2 (0.37) GSK3BGRM2CHRNA7TSHRCHRM5
SCHEMBL3153576 0.96 DAO (0.37) GSK3BGRM2CHRNA7TSHRNCEH1
SCHEMBL6059636 0.94 GSK3B (0.39) GSK3BGRM2CHRNA7TSHRCHRM5
SCHEMBL5684909 0.94 GRM2 (0.36) GSK3BGRM2CHRNA7TSHRCHRM5
SCHEMBL3160311 0.93 ALOX5AP (0.41) GSK3BGRM2CHRNA7TSHRNCEH1
SCHEMBL3158555 0.93 MPL (0.40) GSK3BGRM2TSHRCHRM5PPARA
SCHEMBL3161194 0.92 RARB (0.38) GSK3BGRM2MPL
SCHEMBL3168398 0.92 MPL (0.41) GSK3BGRM2TSHRFFAR1FFAR4
SCHEMBL3165777 0.91 GRM2 (0.38) GSK3BGRM2TSHRCHRM5PPARA
SCHEMBL3166921 0.91 RARB (0.40) GSK3BGRM2TSHRMPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1452514-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2010-03-31 EP disclosed
EP-1273562-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2009-07-22 EP disclosed
US-7145047-B2 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2006-12-05 US disclosed
EP-0952135-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2005-01-05 EP disclosed
EP-1452514-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-09-01 EP disclosed
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-07-24 US disclosed
EP-1273562-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-01-08 EP disclosed
US-6468607-B1 MISCIBILITY, LARGE BIREFRINGENCE INDEX, NO STRONGLY POLAR GROUP IN ITS MOLECULE AND THUS CAN ALSO BE USED FOR ACTIVE MATRIX DRIVING, WIDE TEMPERATURE RANGE AND REQUIRES A HIGH SPEED RESPONSE AND A LOW VOLTAGE DRIVING DAINIPPON INK AND CHEMICALS, INC. (JP) 2002-10-22 US disclosed
EP-0952135-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 1999-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same NLK, NOTCH1, NOTCH4 GSK3B 523/4885GRM2 4698/4885CHRNA7 1650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.